Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT00092742
- Lead Sponsor
- Organon and Co
- Brief Summary
The purpose of this study is to evaluate the long-term safety of an investigational drug versus an approved drug for the relief of pain in patients with rheumatoid arthritis.
- Detailed Description
The duration of treatment is 12 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4086
Inclusion Criteria
- Males and females 50 years or older with rheumatoid arthritis.
Exclusion Criteria
- History of gastrointestinal malabsorption or inflammatory bowel disease
- History of heart problems such as: congestive heart failure (CHF), heart attack or high blood pressure.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Discontinuations due to clinical and laboratory gastrointestinal adverse experiences
- Secondary Outcome Measures
Name Time Method